Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pevonedistat - Takeda Oncology

Drug Profile

Pevonedistat - Takeda Oncology

Alternative Names: MLN-4924; MLN4924-003; Pevonedistat hydrochloride; TAK 924

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Case Western Reserve University; Children's Oncology Group; Eli Lilly and Company; Greehey Childrens Cancer Research Institute; Louisiana State University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Nationwide Children's Hospital; PETHEMA Foundation; Takeda Oncology; Translational Genomics Research Institute; University of Miami; University of Michigan Comprehensive Cancer Center; University of Southampton; University of Southern California; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Antirheumatics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis
  • Discontinued Acute myeloid leukaemia; Cholangiocarcinoma; Chronic myelomonocytic leukaemia; Glioblastoma; Lymphoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-small cell lung cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours

Most Recent Events

  • 09 Dec 2023 Efficacy, pharmacodynamics and adverse events data from the phase I/II trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 10 Nov 2023 Preclinical trials in Rheumatoid arthritis in USA prior to November 2023 (unspecified route)
  • 10 Nov 2023 Pharmacodynamics data from preclinical studies in Rheumatoid arthritis presented at the ACR Convergence 2023 (ACR-ARP-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top